O11 biomedical

RESPILIQ™ - “the liquid breath” Premature babies in the incubator, patients with acute lung failure in the intensive care unit or COPD patients at home: they all suffer from the same potentially fatal condition: hypercapnia = an increased level of CO2 in the blood. In Germany alone there are around 400,000 people a year! Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU and in the outpatient treatment of chronic obstructive pulmonary disease (COPD), which has not yet been adequately solved. Our goal is to revolutionize therapy and significantly improve survival and, above all, the quality of life of these large patient groups suffering from hypercapnia. Instead of tackling the problem through the lungs, RESPILIQ™ uses the human gut as a respiratory organ. The human intestine forms a highly effective exchange membrane for carbon dioxid (CO2). In the gut, RESPILIQ™ can bind CO2 from the intestinal fluid and excrete it via naturalis. Administered orally or rectally, RESPILIQ™ initiates a life-saving reduction of pCO2 in the blood. O11 biomedical GmbH is a spin-off from the Institute for Applied Medical Engineering, Dept. of Biohybrids & Medical Textiles (BioTex) at RWTH Aachen University | Aachen University Hospital. Our team consists of highly dedicated biologists, physicians and engineers. The product development center is located on the Brightlands Chemelot Campus in close cooperation with the Aachen Maastricht Institute for Biobased Materials (AMIBM).

Website

https://www.o11-biomedical.com/

Externer Link zu O11 biomedical

Branche

Herstellung medizinischer Geräte

Größe

2–10 Beschäftigte

Hauptsitz

Aachen, North Rhine-Westphalia

Art

Kapitalgesellschaft (AG, GmbH, UG etc.)

Gegründet

2022